Severe PR3-Dominant Hydralazine-Induced Vasculitis Presenting with C3-Dominant Glomerulonephritis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0770; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Given the presence of >80% crescents and dialysis-dependency, induction therapy was initiated with pulse methylprednisolone, rituximab (375 mg/m 2 x 2), and cyclophosphamide (500 mg IV). This case emphasizes that PR3 positivity does not exclude a drug-induced etiology. In atypical AAV with immune deposits or discordant serologies, clinicians must evaluate for hydralazine toxicity to prevent disease relapse."
Acute Kidney Injury • ANCA Vasculitis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases • Vasculitis • MPO
|
|
Guido M. Capriles; Mohannad Abdeltawwab; Amit K. Rajput
|